于本公告日期，Water Lily：持有合共1.58亿股股份，占已发行股份总数约18.71%;及根据股权激励安排 授予其的受限制股份单位，有权收取6315.65万股股份，惟须遵守该等受限制股份单位的相关条件。 董事会认为，Water Lily上述自愿延长禁售期表明，Water Lily对本公司的未来前景充满信心，并认可本 集团业务的积极发展，包括但不限于本集团候选药物在临床开发和商业化方面取得的重大进展。 智通财经APP讯，拨康视云-B(02592)发布公告，于2025年12月29日，本公司已收到单一最大股东之一 Water Lily Consultants Inc.出具的自愿承诺函件，Water Lily已自愿向本公司承诺，将就本公司股份或其 他证券(或于其中拥有法定或实益权益)延长禁售承诺，延长期限自原禁售期届满的翌日(即2026年1月3 日)(包括当日)起至上述日期起6个月届满之日止(即2026年7月2日)，或本公司与Water Lily另行协定的较 早日期止。自愿承诺仅由Water Lily向本公司作出，并不构成Water Lily对任何其他人(包括承诺函及/或 香港包销协议的任何其他方)的任何义务。 ...

格隆汇12月29日丨讯飞医疗科技(02506.HK)公布，有关公司首次公开发售前投资者持有的股份须受上市 日期起计12个月的禁售期("原禁售期")规限。原禁售期的最后一天为2025年12月29日。 近日，公司接获以下股东的通知： (5)鹿晓亮先生(于合肥正昇、南京正阳及南京正晖信息科技合伙企业(有限合伙)中持有合伙权益，截至 公告日期，其所持有的合伙权益对应公司1,347,531股非上市股份及1,347,531股H股)； (1)科大讯飞股份有限公司("科大讯飞」"截至公告日期持有公司29,869,072股非上市股份及29,869,073股 H股)； (6)尹大海先生(于南京正阳中持有合伙权益，截至公告日期，其所持有的合伙权益对应公司486,825股非 上市股份及486,825股H股)； (2)安徽科讯创业投资基金合伙企业(有限合伙)("科讯创投"，截至公告日期持有公司17,448,567股H股)； (7)吉林先生(于南京正阳中持有合伙权益，截至公告日期，其所持有的合伙权益对应公司292,095股非上 市股份及292,095股H股)；及 (3)赵志伟先生(于公司员工持股平台合肥正昇信息科技合伙企业(有限合伙)( ...

本文源自：财华网 【财华社讯】派格生物医药-B(02565.HK)公布，公司近日接获基石投资者的通知，基石投资者益泽康瑞 医药(香港)有限公司同意自原禁售期(经第一次禁售延长予以延长)届满日期起至2026年4月30日不会以任 何方式减持任何相关H股("第二次禁售延长")。截至本公告日期，基石投资者合共持有958.45万股H股， 占公司已发行H股总数约3.43%。 公司认为，第二次禁售延长表明基石投资者基于公司对推进技术方面的研发能力及在重大临床里程碑方 面取得的重大进展，对公司的未来前景充满信心。基石投资者亦将持续审阅公司业绩，且或会基于实时 发展及所实现的里程碑，考虑进一步延长禁售期。 ...

Core Viewpoint - The stock of Pagoda Biopharmaceuticals-B (02565.HK) opened over 7% higher on November 27, closing at HKD 70.00 per share, an increase of 7.03% due to the announcement of an extended lock-up period by cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd. [2] Group 1: Lock-up Period Extension - Yizhe Kangrui has agreed not to reduce its holdings of H-shares from the original lock-up expiration date until December 31, 2025, extending the lock-up period by 35 days [3] - The extension reflects Yizhe Kangrui's confidence in Pagoda Biopharmaceuticals' technological advancements and significant progress in major clinical milestones [2][3] - Yizhe Kangrui currently holds 9.5845 million H-shares, representing approximately 3.43% of the total issued H-shares of the company [3] Group 2: Company Background and Recent Developments - Pagoda Biopharmaceuticals, established in 2008, focuses on the research and development of innovative therapies for chronic diseases, particularly in the field of metabolic disorders [5] - The company recently received approval for its first product, PB-119 (Vepidna Injection), aimed at improving blood sugar control in adults with type 2 diabetes [6] - Since its listing, Pagoda Biopharmaceuticals has seen a stock price increase of 438.46% over 129 trading days from May 27 to the present [6] Group 3: Financial Performance and Market Outlook - Pagoda Biopharmaceuticals has reported losses of CNY 279 million, CNY 283 million, and CNY 93.62 million for the years 2023, 2024, and the first half of 2025, respectively [6] - A recent report from Softbank China has given Pagoda Biopharmaceuticals a strong buy rating with a target price of HKD 101.80, citing the clinical advantages of PB-119 and potential revenue growth from 2026 to 2029 [6]

Core Viewpoint - The company has received notification from its cornerstone investor, Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., agreeing to extend the lock-up period for its H shares until December 31, 2025, indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1 - The cornerstone investor will not reduce its holdings in any related H shares from the expiration of the original lock-up period [1] - The extension of the lock-up period reflects the cornerstone investor's confidence in the company's research and development capabilities [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]

Core Viewpoint - The announcement highlights the extension of the lock-up period for cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1: Lock-up Agreement - The company entered into a cornerstone investment agreement with Yizhe Kangrui Pharmaceutical, which includes a lock-up commitment for a total of 9,584,500 H shares for a period of 6 months from the listing date [1] - The cornerstone investor currently holds 9,584,500 H shares, representing approximately 3.43% of the company's total issued H shares [1] Group 2: Extension of Lock-up Period - The cornerstone investor has agreed not to reduce their holdings of the relevant H shares from the end of the original lock-up period until December 31, 2025 [1] - The company interprets the extension of the lock-up period as a sign of the cornerstone investor's confidence in the company's ability to advance its technological research and achieve significant clinical milestones [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]